Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-methyl-{4-[2-(7‑oxo‑6,7‑dihydro‑8H‑[1,3]thiazolo[5,4-e]indol‑8‑ylidene)hydrazino]phenyl}methanesulfonamide is a synthetic small molecule belonging to the class of oxindole-based compounds. It was developed as a potent and selective inhibitor of cyclin-dependent kinase 2 (CDK2), an enzyme involved in cell cycle regulation. Structural studies have shown this compound binds to CDK2 with high affinity and selectivity over related kinases such as CDK1. In preclinical research settings it has demonstrated low nanomolar inhibitory activity against CDK2 and can induce cell cycle arrest. This compound has been studied primarily for its potential utility in modulating cell proliferation and for possible prevention of chemotherapy-induced alopecia; however there are no approved clinical indications or ongoing clinical trials for this agent at present.[1][2][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-methyl-{4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide.